On August 5, Novo-Nordisk A/S rose 3.11% in regular trading, trading at 45.655 USD/share, with turnover of 348 million USD.

On the news front, the company reported Q2 adjusted EPS of $0.96, beating the analyst consensus of $0.81 by 18.5%. Revenue came in at $12.209 billion, surpassing the $11.35 billion estimate. The company simultaneously raised its full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations. CEO noted that oral Wegovy has captured approximately 90% of the oral obesity drug market, with 1.5 million patients currently on the tablet form. The CFO also indicated that cost-saving initiatives targeting 8 billion Danish kroner are ahead of schedule.

The rebound follows a nearly 10% plunge last week after the company's cardiovascular drug candidate ziltivekimab failed to meet its primary endpoint in a Phase 3 trial, and reflects market re-pricing of the core GLP-1 franchise's resilience.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)